A single-centre randomised, partially blind, single dose, crossover pilot study investigating the use of stopwatches to assess the onset of action of soothing and cooling of Gaviscon Peppermint Liquid, Double Action Gaviscon Liquid, Gaviscon Advance Liquid and a control in subjects with heartburn following a refluxogenic meal.
- Conditions
- Symptoms of heartburn
- Registration Number
- EUCTR2007-005821-31-GB
- Lead Sponsor
- Reckitt Benckiser Healthcare UK) Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1)Age: = 18 years = 80 years
2)Sex: Male and female subjects are eligible for entry.
3)Status: Members of the Simbec Volunteer Panel who state (self-rated) that they have a tendency to experience symptoms of heartburn related to reflux, following some meals.
4)Primary diagnosis: Those with self-rated at least moderate heartburn within 60 minutes following ingestion of a standardised refluxogenic meal at the screening visit.
5)Subjects who have given written informed consent.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
1)Those who have suffered a recent, significant unexplained weight loss of 6-7kg in the last 6 months.
2)Those who have recently experienced any gastrointestinal bleeding in the last 12 months.
3)Those with difficulty in swallowing.
4)Those with a history and/or symptom profile suggestive of Zollinger-Ellison syndrome, gastric carcinoma, previous or current peptic ulcer disease, pernicious anaemia, Barrett’s oesophagus or systemic sclerosis.
5)Those with known hypophosphataemia or phenylketonuria.
6)Those with severe constipation or history of colonic stenosis.
7)Those who have taken any antacids, H2 antagonists, motility stimulants/prokinetics or other medicines for relief of symptoms of acid reflux disease within the previous 24 hours prior to screening.
8)Those who have taken proton pump inhibitors within the previous 48 hours prior to screening.
9)Those with a history of drug, solvent or alcohol abuse.
10)Those with any previous history of allergy or known intolerance to any of the study drugs or following formulation constituents, sodium alginate or potassium bicarbonate.
11)Those who are receiving treatment for their gastrointestinal problems or gastro-oesphageal reflux disease from their GP.
12)Those unable in the opinion of the Investigator to comply fully with the study requirements.
13)Those currently participating in a clinical study or who have participated in any other clinical study within the last 30 days.
14)Those who have previously participated in this randomised study.
15)Woman of childbearing potential, who are pregnant or lactating, seeking pregnancy or failing to take adequate contraceptive precautions, (i.e. an oral or injectable contraceptive, an approved hormonal implant or topical patch, an intrauterine device, abstinence [should the subject become sexually active, she must agree to use a double barrier method] or condoms/diaphragm and spermicide). A woman of childbearing potential is defined as any female who is less than 2 years post-menopausal or has not undergone an hysterectomy or surgical sterilisation, e.g. bilateral tubal ligation, bilateral ovariectomy (oophorectomy).
16) Those who are on steroids or non-steroidal anti-inflammatory drugs.
17) Those who are diabetics.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method